Taikang Asset Management Hong Kong Co Ltd Has $10.49 Million Stock Position in IQVIA Holdings Inc. $IQV

Taikang Asset Management Hong Kong Co Ltd increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 11.5% in the 4th quarter, Holdings Channel reports. The firm owned 46,543 shares of the medical research company’s stock after buying an additional 4,817 shares during the quarter. IQVIA comprises approximately 1.0% of Taikang Asset Management Hong Kong Co Ltd’s investment portfolio, making the stock its 26th biggest position. Taikang Asset Management Hong Kong Co Ltd’s holdings in IQVIA were worth $10,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA during the 4th quarter worth about $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter worth about $27,000. Measured Wealth Private Client Group LLC bought a new position in IQVIA during the third quarter worth about $30,000. Finally, Activest Wealth Management boosted its holdings in IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $179.04 on Wednesday. The business’s fifty day moving average is $173.77 and its two-hundred day moving average is $192.69. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $29.88 billion, a P/E ratio of 22.19, a P/E/G ratio of 1.53 and a beta of 1.21. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IQV. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Royal Bank Of Canada initiated coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. HSBC set a $210.00 price target on IQVIA in a research report on Wednesday, June 3rd. Evercore reissued an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Finally, Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.